Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
Authors:
- 20 June 2017
- journal article
- letter
- Published by Wolters Kluwer Health in Circulation
- Vol. 135 (25) , 2572-2574
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseNew England Journal of Medicine, 2017
- Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care ActAmerican Heart Journal, 2016
- Ezetimibe Added to Statin Therapy after Acute Coronary SyndromesNew England Journal of Medicine, 2015
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsCirculation, 2014